Amyloid

The Journal of Protein Folding Disorders

Volume 26, 2019 - Issue 2

229

Views

CrossRef citations to date

Altmetric

Letter to the Editor

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

Lisa Xingguang LeeThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Ping ZhouThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Cindy VargaThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Teresa FogarenThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Katelynn HoTufts University School of Medicine, Boston, MA, USA

Xun MaThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Melissa WarnerThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA

Denis ToskicThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA

http://orcid.org/0000-0002-3340-762X

Adin KugelmassThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA

Raymond L. ComenzoThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA;Department of Pathology and Clinical Laboratory Medicine, Tufts Medical Center, Boston, MA, USACorrespondence[email protected]

http://orcid.org/0000-0002-6255-5824

show all

"Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms." Amyloid, 26(2), pp. 101–102

Disclosure statement

No potential conflict of interest was reported by the authors.

Acknowledgements

The authors thank the Division of Hematology-Oncology and Departments of Medicine and Pathology and Laboratory Medicine at Tufts for their continued support, and also acknowledge the support by the Amyloidosis and Myeloma Research Fund at Tufts, the Cam Neely and John Davis Myeloma Research Fund, the John C Davis Program for Myeloma and Amyloid at Tufts, the Sidewater Family Fund, the Lavonne Horowitz Trust, the Werner and Elaine Dannheiser Fund for Research on the Biology of Aging of the Lymphoma Foundation, David and Barbara Levine (in memoriam), and the Demarest Lloyd Jr Foundation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

Information for

Open access

Opportunities

Help and information

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

Disclosure statement

Acknowledgements

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature